Related Experiment Video

Updated: Aug 7, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

Jaundice in the preterm infant

Pamela Truman1

  • 1South Birmingham Primary Care Trust.

Paediatric Nursing
|June 21, 2006
PubMed

Insights

Jaundice in preterm infants, known as hyperbilirubinaemia, affects 80%. While phototherapy is common, its effectiveness and management protocols require more evidence-based research for optimal infant care.

Area of Science:

  • Neonatal Medicine
  • Pediatric Gastroenterology

Background:

  • Hyperbilirubinaemia (jaundice) affects approximately 80% of preterm infants.
  • Current treatments include phototherapy and exchange transfusion.
  • Management protocols for phototherapy in preterm infants lack consistent evidence.

Purpose of the Study:

  • To review the evidence surrounding phototherapy for preterm infant jaundice.
  • To identify controversies and gaps in current treatment guidelines.
  • To emphasize the need for evidence-based research in neonatal jaundice management.

Main Methods:

  • Literature review of existing studies on phototherapy for preterm infants.
  • Analysis of conflicting evidence regarding fluid management, thermoregulation, and complication prevention.
  • Identification of areas requiring further research.

Main Results:

  • Phototherapy is a common treatment for preterm infant jaundice.
  • Evidence supporting optimal phototherapy management, including fluid and thermoregulation, is conflicting.
  • The apparent success of phototherapy is not consistently evidence-based.

Conclusions:

  • Further research is crucial for developing effective treatments for preterm infant jaundice.
  • Establishment of evidence-based guidelines for phototherapy is needed.
  • Addressing management controversies will improve care for jaundiced preterm infants.

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...